Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Common Equity (2020 - 2026)

MoonLake Immunotherapeutics' Common Equity history spans 7 years, with the latest figure at $254.0 million for Q1 2026.

  • Quarterly Common Equity fell 38.43% to $254.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $254.0 million through Mar 2026, down 38.43% year-over-year, with the annual reading at $304.5 million for FY2025, 32.84% down from the prior year.
  • Common Equity came in at $254.0 million for Q1 2026, down from $304.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $552.4 million in Q1 2024 to a low of -$25.3 million in Q1 2022.
  • The 5-year median for Common Equity is $357.9 million (2025), against an average of $319.6 million.
  • The largest YoY upside for Common Equity was 11310.99% in 2022 against a maximum downside of 10205.8% in 2022.
  • MoonLake Immunotherapeutics' Common Equity stood at $68.8 million in 2022, then soared by 646.71% to $513.5 million in 2023, then decreased by 11.7% to $453.4 million in 2024, then crashed by 32.84% to $304.5 million in 2025, then fell by 16.57% to $254.0 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Common Equity are $254.0 million (Q1 2026), $304.5 million (Q4 2025), and $291.2 million (Q3 2025).